Thursday, June 8, 2017
- 1:15pm-2:45pm
-
Antiparkinson and antioxidant effect of N-Methanesulfonylpyrazolinyl substituted Heterosteroids in LPS induced Neuroinflammation Model of Rats
Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Exhibit Hall C
- 1:15pm-2:45pm
-
Anxiety influences the neural correlates associated with freezing of gait in Parkinson’s disease
Parkinson's Disease: Neuroimaging And Neurophysiology · Exhibit Hall C
- 1:15pm-2:45pm
-
Aquatic Dual Task Exercise: Effects on Body Balance of Individuals with Parkinson’s Disease
Clinical Trials and Therapy in Movement Disorders · Exhibit Hall C
- 1:15pm-2:45pm
-
Aquatic Physical Exercises: Balance in People with Parkinson’s Disease
Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Exhibit Hall C
- 1:15pm-2:45pm
-
Are the exergaming effective for improving functional exercise capacity, and quality of life in Patients with Parkinson’s Disease?
Clinical Trials and Therapy in Movement Disorders · Exhibit Hall C
- 1:15pm-2:45pm
-
Assessing cholinergic innervation in Parkinson’s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol
Parkinson's Disease: Neuroimaging And Neurophysiology · Exhibit Hall C
- 1:15pm-2:45pm
-
Assessing Nigral Functional Connectivity in Parkinson’s Disease with Resting State Functional MRI
Parkinson's Disease: Neuroimaging And Neurophysiology · Exhibit Hall C
- 1:15pm-2:45pm
-
Assessing the involvement of ARSG and RAB12 variants in Musician’s Focal Dystonia from the US.
Dystonia · Exhibit Hall C
- 1:15pm-2:45pm
-
Assessment of substantia nigra degeneration with magnetic resonance and transcranial ultrasonography
Parkinson's Disease: Neuroimaging And Neurophysiology · Exhibit Hall C
- 1:15pm-2:45pm
-
Associating patient impression of improvement with efficacy endpoints in Parkinson’s disease: A post-hoc analysis of a tozadenant study
Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Exhibit Hall C
- «Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 41
- Next Page»